Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Urology
Volume 2014, Article ID 489686, 3 pages
Case Report

Nanoparticle Albumin-Bound-Paclitaxel in the Treatment of Metastatic Urethral Adenocarcinoma: The Significance of Molecular Profiling and Targeted Therapy

1Department of Internal Medicine, Florida Hospital, Orlando, FL 32804, USA
2Cancer Institute of Florida, Florida Hospital, 2501 North Orange Avenue, Suite 689, Orlando, FL 32804, USA

Received 24 June 2014; Accepted 6 August 2014; Published 18 August 2014

Academic Editor: Fumitaka Koga

Copyright © 2014 Yasmin M. Abaza and Carlos Alemany. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Primary urethral cancer is rare and accounts for only 0.003% of all malignancies arising from the female genitourinary tract. Due to the rarity of this disease, no consensus exists regarding the optimal therapeutic approach. Nanoparticle albumin-bound-paclitaxel has been shown to be effective in the treatment of a number of malignancies including metastatic breast, pancreatic, and bladder cancer. We present a 67-year-old woman with advanced metastatic urethral adenocarcinoma resistant to two lines of chemotherapy (ifosfamide/paclitaxel/cisplatin and irinotecan/5-fluorouracil/leucovorin) that showed a dramatic response to nanoparticle albumin-bound-paclitaxel. This is the first case report to document the use and efficacy of nanoparticle albumin-bound-paclitaxel in the treatment of unresectable metastatic urethral cancer.